GO
| HSI1 | 24,856.43 | 0.00 | -- |
| HSCEI1 | 8,389.93 | 0.00 | -- |
| Back Zoom + Zoom - Block Traded | |
|
2026-03-26 12:02:04 BofA Securities released a research report on WUXI BIO (02269.HK), which saw its revenue ascend by 16.7% YoY to RMB21.8 billion in 2025, in line. The gross profit reached RMB10 billion, with the GPM up by 5 ppts to 46%, on the back of more contribution from royalty/ milestones with higher margins and enhanced capacity utilization. The net profit attributable to shareholders was RMB4.9 billion, up 46.3% from the same period last year. The broker revised down its revenue forecast for 2026-28 by 4-8% and lowered the GPM by 0.4 ppts. The target price was chopped from HKD47 to HKD39.5, with a Neutral rating. ~ AASTOCKS Financial News Website: www.aastocks.com | |